GlassScriptPhysician profile
Sini Thomas
NPI 1740729847
$7,046.12
in general payments reported to CMS, 2019-2025
32 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,853 · 2022: $1,231 · 2023: $1,386 · 2024: $1,303 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,961.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,402.82 | 2021 | |
| Novo Nordisk INC | $976.89 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Gilead Sciences, INC. | $666.94 | 2023-2025 | Epclusa, Livdelzi, Vemlidy |
| Abbvie INC. | $609.98 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $431.24 | 2022-2025 | Farxiga, Saphnelo |
| Inspire Medical Systems, INC. | $226.56 | 2023-2024 | Inspire |
| Genzyme Corporation | $218.31 | 2023-2024 | |
| Abbott Laboratories | $197.75 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $190.78 | 2022-2023 | |
| Madrigal Pharmaceuticals | $139.99 | 2025 | Rezdiffra |
| Silk Road Medical, INC. | $133.75 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Coloplast Corp | $133.30 | 2023-2024 | Altis, Titan |
| Csl Behring | $124.64 | 2024 | Hizentra |
| Lilly USA, LLC | $121.52 | 2024 | Zepbound |
| Acadia Pharmaceuticals INC | $120.99 | 2024 | Daybue |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $113.35 | 2025 | Korlym |
| Amgen INC. | $109.41 | 2021 | |
| Emd Serono, INC. | $102.05 | 2024 | |
| Axsome Therapeutics, INC. | $97.61 | 2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $93.62 | 2022 | |
| Edwards Lifesciences Corporation | $89.89 | 2022 | |
| Sk Life Science, INC. | $85.35 | 2022 | |
| Mylan Specialty L.P. | $85.09 | 2023 | Yupelri |
| Exact Sciences Corporation | $83.52 | 2023-2025 | Cologuard Collection Kit |
| Abiomed | $82.00 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.31 | 2022 | |
| Stemline Therapeutics INC. | $77.88 | 2022 | |
| Jazz Pharmaceuticals INC. | $77.88 | 2025 | |
| Pfizer INC. | $60.84 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.94 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.72 | 2021 | |
| Nevro Corp. | $28.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sini Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.